846 related articles for article (PubMed ID: 32027911)
1. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis.
Kalligeros M; Vassilopoulos A; Shehadeh F; Vassilopoulos S; Lazaridou I; Mylonakis E; Promrat K; Wands JR
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1708-1722. PubMed ID: 36642292
[TBL] [Abstract][Full Text] [Related]
3. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
4. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies.
Le P; Payne JY; Zhang L; Deshpande A; Rothberg MB; Alkhouri N; Herman W; Hernandez AV; Schleicher M; Ye W; Dasarathy S
Clin Gastroenterol Hepatol; 2023 May; 21(5):1154-1168. PubMed ID: 35933075
[TBL] [Abstract][Full Text] [Related]
5. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Ng CH; Lim WH; Hui Lim GE; Hao Tan DJ; Syn N; Muthiah MD; Huang DQ; Loomba R
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):931-939.e5. PubMed ID: 35513235
[TBL] [Abstract][Full Text] [Related]
6. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.
Sarkar MA; Suzuki A; Abdelmalek MF; Yates KP; Wilson LA; Bass NM; Gill R; Cedars M; Terrault N;
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1267-1274.e1. PubMed ID: 33010412
[TBL] [Abstract][Full Text] [Related]
7. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
[TBL] [Abstract][Full Text] [Related]
9. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Le MH; Le DM; Baez TC; Dang H; Nguyen VH; Lee K; Stave CD; Ito T; Wu Y; Yeo YH; Ji F; Cheung R; Nguyen MH
Clin Mol Hepatol; 2024 Apr; 30(2):235-246. PubMed ID: 38281814
[TBL] [Abstract][Full Text] [Related]
10. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Soppert J; Brandt EF; Heussen NM; Barzakova E; Blank LM; Kuepfer L; Hornef MW; Trebicka J; Jankowski J; Berres ML; Noels H
Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2746-2758. PubMed ID: 36470528
[TBL] [Abstract][Full Text] [Related]
11. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
[TBL] [Abstract][Full Text] [Related]
13. Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women.
Maldonado SS; Cedars MI; Yates KP; Wilson LA; Gill R; Terrault NA; Suzuki A; Sarkar MA
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):339-346.e5. PubMed ID: 37678489
[TBL] [Abstract][Full Text] [Related]
14. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.
Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
Ann Hepatol; 2024; 29(3):101288. PubMed ID: 38278181
[TBL] [Abstract][Full Text] [Related]
15. High parathyroid hormone level as a marker of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Jaroenlapnopparat A; Rittiphairoj T; Chaisidhivej N; Walker B; Charoenngam N
Diabetes Metab Syndr; 2023 Aug; 17(8):102827. PubMed ID: 37451113
[TBL] [Abstract][Full Text] [Related]
16. Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Ha J; Yim SY; Karagozian R
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2496-2507.e5. PubMed ID: 36442727
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of Neutrophil to Lymphocyte Ratio in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Shavakhi M; Nourigheimasi S; Dioso E; Goutnik M; Lucke-Wold B; Khanzadeh S; Heidari F
Can J Gastroenterol Hepatol; 2022; 2022():1554079. PubMed ID: 37601979
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
Sanyal AJ; Shankar SS; Yates KP; Bolognese J; Daly E; Dehn CA; Neuschwander-Tetri B; Kowdley K; Vuppalanchi R; Behling C; Tonascia J; Samir A; Sirlin C; Sherlock SP; Fowler K; Heymann H; Kamphaus TN; Loomba R; Calle RA
Nat Med; 2023 Oct; 29(10):2656-2664. PubMed ID: 37679433
[TBL] [Abstract][Full Text] [Related]
19. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
[TBL] [Abstract][Full Text] [Related]
20. African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians.
Satapathy SK; Marella HK; Heda RP; Ganguli S; Kirthi Reddy Y; Podila PSB; Clark I; Maliakkal B
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):388-398. PubMed ID: 32317586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
